[2] [3] However, clinical judgment should guide individualized monitoring strategies based on patient-specific factors and baseline hepatic status
In patients with type 2 diabetes, liraglutide reduces A1C by approximately 0.5%
Moreover, small-molecule GLP-1RAs offer a solution to the bioavailability limitations faced by oral peptide-based agents, which often depend on absorption enhancers (e.g., SNAC) and strict fasting protocols [74]
If you carry it out in the open, it is likely to be bumped or broken
Overall, the addition of oral semaglutide 7 mg or 14 mg compared favorably to the addition of sitagliptin 100 mg in patients with T2DM inadequately controlled on metformin sulfonylurea background therapy
This is the smallest adjustment you can make and carries virtually no additional risk